Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression

References

• de Silva HV, Harmony JA, Stuart WD, Gil CM, Robbins J. Apolipoprotein J: structure and tissue distribution. Biochemistry. 1990;29:5380–9.
   PubMed Web of Science ®Google Scholar
• Wilson MR, Easterbrook-Smith SB. Clusterin is a secreted mammalian chaperone. Trends Biochem Sci. 2000;25:95–8.
   PubMed Web of Science ®Google Scholar
• Trougakos IP, Gonos ES. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol. 2002;34:1430–48.
   PubMed Web of Science ®Google Scholar
• Leskov KS, Klokov DY, Li J, Kinsella TJ, Boothman DA. Synthesis and functional analysis of nuclear clusterin: a cell death protein. J Biol Chem. 2003;278:11590–600.
   PubMed Web of Science ®Google Scholar
• Caccamo AE, Scaltriti M, Caporali A, D’Arca D, Scorcioni F, Candiano G, et al.. Ca2+ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. Cell Death Differ. 2005;12:101–4.
   PubMed Web of Science ®Google Scholar
• Redondo M, Villar E, Torres-Muñoz J, Tellez T, Morell M, Petito CK. Overexpression of clusterin in human breast carcinoma. Am J Pathol. 2000;157:393–9.
   PubMed Web of Science ®Google Scholar
• Yom CK, Woo HY, Min SY, Kang SY, Kim HS. Clusterin overexpression and relapse-free survival in breast cancer. Anticancer Res. 2009;29:3909–12.
   PubMed Web of Science ®Google Scholar
• Li J, Jia L, Zhao P, Jiang Y, Zhong S, Chen D. Stable knockdown of clusterin by vectorbased RNA interference in a human breast cancer cell line inhibits tumour cell invasion and metastasis. J Int Med Res. 2012;40:545–55.
   PubMed Web of Science ®Google Scholar
• Trougakos IP, Gonos ES. Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases. Free Radic Res. 2006;40:1324–34.
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Santamaria A, Paciucci R, Bettuzzi S. Intracellular clusterin induces G2–M phase arrest and cell death in PC-3 prostate cancer cells. Cancer Res. 2004;64:6174–82.
   PubMed Web of Science ®Google Scholar
• Thomas-Tikhonenko A, Viard-Leveugle I, Dews M, Wehrli P, Sevignani C, Yu D, et al.. Myc-transformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo. Cancer Res. 2004;64:3126–36.
   PubMed Web of Science ®Google Scholar
• Shannan B, Seifert M, Leskov K, Willis J, Boothman D, Tilgen W, et al.. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death Differ. 2006;13:12–9.
   PubMed Web of Science ®Google Scholar
• Flanagan L, Whyte L, Chatterjee N, Tenniswood M. Effects of clusterin over-expression on metastatic progression and therapy in breast cancer. BMC Cancer. 2010;10:107.
   PubMedGoogle Scholar
• So A, Sinnemann S, Huntsman D, Fazli L, Gleave M. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo. Mol Cancer Ther. 2005;4:1837–49.
   PubMed Web of Science ®Google Scholar
• Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9:361–71.
   PubMed Web of Science ®Google Scholar
• Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10:45–65.
   PubMed Web of Science ®Google Scholar
• Danial NN, Korsmeyer SJ. Cell death. Critical control points. Cell. 2004;116:205–19.
   PubMed Web of Science ®Google Scholar
• Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, et al.. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell. 2007;12:445–56.
   PubMed Web of Science ®Google Scholar
• Hoffmann A, Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev. 2006;210:171–86.
   PubMed Web of Science ®Google Scholar
• Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006;25:6680–4.
   PubMed Web of Science ®Google Scholar
• Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol. 2002;3:221–7.
   PubMed Web of Science ®Google Scholar
• Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature. 1995;376:167–70.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72:1605–21.
   PubMed Web of Science ®Google Scholar
• Giri DK, Aggarwal BB. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem. 1998, 273:14008–14.
   PubMed Web of Science ®Google Scholar
• Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q. Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression. Mol Cancer. 2011;10:106.
   PubMed Web of Science ®Google Scholar
• Wu J, Shao ZM, Shen ZZ, Lu JS, Han QX, Fontana JA, et al.. Significance of apoptosis and apoptotic-related proteins, Bcl-2, and Bax in primary breast cancer. Breast J. 2000;6:44–52.
   PubMedGoogle Scholar
• Mattson MP, Camandola S. NF-kappaB in neuronal plasticity and neurodegenerative disorders. J Clin Invest. 2001;107:247–54.
   PubMed Web of Science ®Google Scholar
• Tanabe K, Kim R, Inoue H, Emi M, Uchida Y, Toge T. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs. Int J Oncol. 2003;22:875–81.
   PubMed Web of Science ®Google Scholar
• Zellweger T, Kiyama S, Chi K, Miyake H, Adomat H, Skov K, et al.. Overexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour model. BJU Int. 2003;92:463–9.
   PubMed Web of Science ®Google Scholar
• July LV, Beraldi E, So A, Fazli L, Evans K, English JC, et al.. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther. 2004;3:223–32.
   PubMed Web of Science ®Google Scholar
• Santilli G, Aronow BJ, Sala A. Essential requirement of apolipoprotein J (clusterin) signaling for IkappaB expression and regulation of NF-kappaB activity. J Biol Chem. 2003;278:38214–9.
   PubMed Web of Science ®Google Scholar
• Essabbani A, Margottin-Goguet F, Chiocchia G. Identification of clusterin domain involved in NF-kappaB pathway regulation. Biol Chem. 2010;285:4273–7.
   Web of Science ®Google Scholar
• Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene. 2008,27:6398–406.
   PubMed Web of Science ®Google Scholar
• Deng X, Ruvolo P, Carr B, May EV. Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc Natl Acad Sci USA. 2000;97:1578–3.
   PubMed Web of Science ®Google Scholar